Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travoprost + brinzolamide fixed combination once nightly versus Travatan for 24-hour IOP control
2008-002750-38Phase 2Terminated
- Sponsor
- Alcon Inc.
- Start
- Oct 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of travoprost and brinzolamide in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Mean nocturnal intraocular pressure. Started Oct 2008; status: terminated.
02
Drugs
travoprostbrinzolamide
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2008-002750-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002750-38.